White House launches TrumpRx.gov, pushes MFN drug pricing on AstraZeneca and peers

Washington presses global drugmakers with new TrumpRx.gov rollout

The White House launches TrumpRx.gov as an administration-backed portal offering consumers access to prescription medicines at prices negotiated under so-called most-favoured-nation (MFN) deals, a move that directly targets pricing practices of large global pharmaceutical firms including AstraZeneca. President Donald Trump announces that the United States will pay the lowest prices any other country pays under the agreements, and that discounts will be passed through to cash-paying consumers via the site. He says price reductions compared with current U.S. levels may range “by differences of as much as 300, 400, 500, even 600%,” arguing the U.S. pays disproportionately more for medicines.

The initiative ties participation to concessions, with the administration saying 16 of the 17 largest drugmakers have accepted MFN pricing terms for federal programmes and agreed to extend those reduced rates to the public; participating firms receive exemptions from U.S. tariffs in return. AstraZeneca, as one of the sector’s largest players, falls squarely within the policy’s scope and faces heightened scrutiny over its international launch and pricing strategies as Washington seeks to align U.S. costs with global benchmarks. Industry officials and health policy analysts say the move could force manufacturers to reassess differential pricing and patient access policies, while also spotlighting trade and regulatory levers as tools to lower domestic drug costs.

The rollout raises questions for development and supply strategies, particularly for companies with large portfolios of oncology and specialty medicines where list prices vary widely by market. Manufacturers contend that cross-market price harmonization can affect revenue streams that fund research and development, and they are navigating how to reconcile MFN commitments with existing contracts, rebates and supply arrangements. For AstraZeneca, which operates extensive global distribution networks, the program creates a fresh policy landscape in which commercial, regulatory and manufacturing plans are likely to be reviewed to ensure compliance and continued patient access.

Design partners and media attention

The launch features CMS Administrator Dr. Mehmet Oz and Joe Gebbia, Airbnb’s co-founder, advising on the portal’s digital design and user experience; the administration says the site makes discounts available “directly to consumers starting today.”

Media reporting highlights Pfizer commentary on earnings and the competitive market for weight-loss drugs, underscoring broader industry attention as the White House presses for wider company participation amid public concern on drug costs reflected in recent polls.